Current Opinion in Gastroenterology最新文献

Kupffer cells are central to mitigating intravascular infections. 库普弗细胞是缓解血管内感染的核心。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-07-30 DOI: 10.1097/MOG.0000000000001128

Filipe Rodolfo Moreira Borges Oliveira, Paul Kubes

引用次数: 0

Endobariatrics in the era of glucagon-like peptide-1 receptor agonists: evolving roles, evidence, and integration. 胰高血糖素样肽-1受体激动剂时代的内分泌：进化的作用、证据和整合。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-10-02 DOI: 10.1097/MOG.0000000000001134

Farnoosh Vahedi, Meghna Yalamanchi, Danny Issa

{"title":"Endobariatrics in the era of glucagon-like peptide-1 receptor agonists: evolving roles, evidence, and integration.","authors":"Farnoosh Vahedi, Meghna Yalamanchi, Danny Issa","doi":"10.1097/MOG.0000000000001134","DOIUrl":"https://doi.org/10.1097/MOG.0000000000001134","url":null,"abstract":"Purpose of review: We review and summarize current evidence-based management strategies in the field of endobariatrics (EBT) for the management of obesity during a time of rapidly expanding pharmacologic options, particularly with rising popularity of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs).Recent findings: National trends show increased use of GLP-1 RAs in obesity management. EBT are minimally invasive endoscopic therapies that offer durable weight loss with low complications rates. Patient comorbidities, socioeconomic factors, and adherence are critical considerations in treatment selection. Emerging data suggest that combining GLP-1 RAs with EBTs may yield synergistic effects.Summary: A growing array of treatment options are available in the management of obesity. Personalized, combination therapy that integrates mechanism-based interventions with pharmacotherapy may optimize long-term outcomes for sustained weight loss. Multidisciplinary approach remains essential for delivering comprehensive multidisciplinary care.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"41 6","pages":"380-388"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in diagnosis and therapy for upper gastrointestinal Crohn's disease. 上消化道克罗恩病的诊断和治疗进展。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-08-01 DOI: 10.1097/MOG.0000000000001129

Laura Sahyoun, Jill K J Gaidos

{"title":"Advances in diagnosis and therapy for upper gastrointestinal Crohn's disease.","authors":"Laura Sahyoun, Jill K J Gaidos","doi":"10.1097/MOG.0000000000001129","DOIUrl":"10.1097/MOG.0000000000001129","url":null,"abstract":"Purpose of review: Crohn's disease is a chronic, relapsing and remitting inflammatory process that can involve the entire length of the gastrointestinal tract. Upper gastrointestinal involvement (UGI) in Crohn's disease is present in up to 15% of patients and can present as a diagnostic challenge given nonspecific symptoms and overlapping disease entities. This review provides an update on diagnosing and risk stratifying UGI-CD.Recent findings: Literature suggests the use of imaging modalities (such as video capsule endoscopy, cross-sectional imaging and intestinal ultrasound) to help identify proximal inflammation when clinical suspicion for UGI involvement exists based on symptoms and patient factors. Additionally, proximal disease involvement has been associated with increased disease severity, a higher prevalence of strictures and an increased risk for surgery. First-line therapies are corticosteroids and antitumor necrosis factor therapies if systemic treatment is needed based on disease severity. For stricturing disease, endoscopic balloon dilation, strictureplasty, surgical resection or bypass can be considered for medically refractory or recurrent disease.Summary: As the prevalence and progression of UGI-CD is still understudied due to its variable definition, presentation and incidence, the development of a standardized approach to diagnosis could aid in determining the overall prevalence and most effective treatments.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"426-431"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing care in malignant gastric outlet obstruction: a contemporary review of management strategies. 推进恶性胃出口梗阻的护理：当代管理策略回顾。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-04-23 DOI: 10.1097/MOG.0000000000001101

Adrianna Wierzbicka, Tilak Shah

{"title":"Advancing care in malignant gastric outlet obstruction: a contemporary review of management strategies.","authors":"Adrianna Wierzbicka, Tilak Shah","doi":"10.1097/MOG.0000000000001101","DOIUrl":"10.1097/MOG.0000000000001101","url":null,"abstract":"Purpose of review: The aim of this review is to summarize the most pertinent data on management of malignant gastric outlet obstruction (MGOO), with an emphasis on recent updates.Recent findings: Traditionally, options to restore luminal patency in patients with MGOO were surgical gastrojejunostomy (SGJ) and endoscopic insertion of an enteral stent. The latter was reserved for patients with poor performance status or anticipated survival less than 2 months. Endoscopic gastroenterostomy (EUS-GE) is a newer technique that aims to mimic a SGJ and involves placement of a lumen apposing metal stent (LAMS) from the stomach directly into the jejunum. In a recent randomized trial of EUS-GE vs. enteral stent, the former was associated with reduced re-interventions, improved stent patency, and improved patient reported eating habits. Recent publications suggest that EUS-GE may offer substantial advantages over S-GJ; a randomized trial is currently underway. Venting gastrostomy may be the most suitable option for patients with markedly impaired gastric motility or with multiple luminal obstructions.Summary: MGOO is a debilitating late complication of advanced upper gastrointestinal malignancies, resulting from blockage or mechanical compression of the distal stomach, pyloric antrum or duodenum. Various modalities are currently available, and should be tailored to patient's expectations, underlying cause, life expectancy, and functional status.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"409-415"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modern concepts of small intestinal bacterial overgrowth. 小肠细菌过度生长的现代概念。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1097/MOG.0000000000001135

Gillian M Barlow, Mark Pimentel

{"title":"Modern concepts of small intestinal bacterial overgrowth.","authors":"Gillian M Barlow, Mark Pimentel","doi":"10.1097/MOG.0000000000001135","DOIUrl":"10.1097/MOG.0000000000001135","url":null,"abstract":"Purpose of review: Small intestinal bacterial overgrowth (SIBO) has been a recognized condition for more than half a century. Early descriptions of SIBO were based on the concept of colonic bacteria \"backing up\" into the small intestine. This was based on techniques using unprotected aspiration catheters and earlier culture techniques. Recent advances in breath testing, small bowel sampling, culture techniques, and next generation sequencing have helped expand our understanding of SIBO.Recent findings: \"SIBO\" is now understood to encompass at least three different types of overgrowth including SIBO, intestinal methanogen overgrowth (IMO) and intestinal sulfide overproduction (ISO). Each has their own unique microbial profile. In addition, next generation sequencing has revealed that SIBO is not a migration of colonic flora into the small intestine, but rather overgrowth of two predominant species/strains from phylum Proteobacteria ( Escherichia coli and Klebsiella ). Lastly, results from next generation sequencing of the stool and small intestinal microbiomes have validated breath testing as a diagnostic tool.Summary: Together, these advances have allowed the identification of key microbes in overgrowth syndromes, uncovering their relationships to conditions such as irritable bowel syndrome, and paving the way for the development of novel customized treatment options in the future.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"399-408"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stomach and duodenum: what's current in 2025. 胃和十二指肠：2025年的样子。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-10-02 DOI: 10.1097/MOG.0000000000001130

Tilak U Shah

引用次数: 0

Potassium-competitive acid blockers. 钾竞争性酸阻滞剂。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-07-23 DOI: 10.1097/MOG.0000000000001127

Trevor A Davis, C Prakash Gyawali

{"title":"Potassium-competitive acid blockers.","authors":"Trevor A Davis, C Prakash Gyawali","doi":"10.1097/MOG.0000000000001127","DOIUrl":"10.1097/MOG.0000000000001127","url":null,"abstract":"Purpose of review: Acid suppression is the mainstay of management of common foregut disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori infection. Drawbacks of standard management with proton pump inhibitors (PPIs) include acid lability requiring enteric coating, slow onset of effect, lack of suppression of nocturnal acid breakthrough, and need for administration before meals.Recent findings: Potassium-competitive acid blockers (PCABs) are a novel class of acid suppressants that are effective in the management of symptomatic and erosive GERD, peptic ulcer disease and H. pylori infection. Administration before meals is not needed, and these agents achieve profound acid suppression right from the first dose, with control of daytime as well as nocturnal acid. In randomized controlled trials, PCABs are noninferior and often superior to PPIs, especially in healing of advanced grade esophagitis and eradication of treatment-naive as well as refractory H. pylori. The safety profile of PCABs over 10 years of use is reassuring, although profound acid suppression may contribute to hypergastrinemia and increased risk of gastrointestinal infections.Summary: As PCABs become available in many countries around the globe, real-world use will allow further research to determine the clinical niche of these acid-suppressive agents.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"389-398"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in endoscopic hemostasis for nonvariceal gastroduodenal bleeding. 内镜下止血治疗非静脉曲张胃十二指肠出血的最新进展。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-11-01 Epub Date: 2025-09-17 DOI: 10.1097/MOG.0000000000001133

Himesh B Zaver, Mary S McGrath, Andrew Y Wang

引用次数: 0

Beyond the scope: an update on colon cancer screening tests. 超出范围：结肠癌筛查测试的最新进展。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-09-25 DOI: 10.1097/MOG.0000000000001138

Timothy Yen, Minh Do, Swati G Patel

{"title":"Beyond the scope: an update on colon cancer screening tests.","authors":"Timothy Yen, Minh Do, Swati G Patel","doi":"10.1097/MOG.0000000000001138","DOIUrl":"https://doi.org/10.1097/MOG.0000000000001138","url":null,"abstract":"Purpose of review: Colorectal cancer (CRC) is common and rising among persons under age 50, but screening uptake is sub-optimal, particularly in 45-49 year-olds. Death from CRC can be prevented through detection and removal of advanced precancerous colorectal lesions (APLS) or detection of CRC at an early stage. In this review, we cover average-risk CRC screening options and present a framework for test selection in different clinical settings.Recent findings: The optimal CRC screening test should be highly sensitive for APLs and early stage CRC, easy to access, affordable to patient and payers, and appropriate for screening settings. Organized screening is administered systematically on the population-level, while opportunistic screening relies on individual provider-patient shared decision making. In addition to established options such as fecal immunochemical testing, multitarget stool DNA testing, and colonoscopy, novel options include stool-based RNA testing, next-generation stool-based DNA testing, and blood-based DNA testing. Although blood-based tests may be convenient, their low sensitivity for APLs can unintentionally lead to negative consequences for CRC prevention.Summary: Uptake, cost, and efficacy of established and novel CRC screening tests influence the modality of choice for specific screening settings. Colonoscopy and stool-based tests should generally be first-line for CRC screening.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laxative logic: when lifestyle is not enough. 通便逻辑：当生活方式不够时。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-09-25 DOI: 10.1097/MOG.0000000000001137

Rachel Colbran, Leila Neshatian

{"title":"Laxative logic: when lifestyle is not enough.","authors":"Rachel Colbran, Leila Neshatian","doi":"10.1097/MOG.0000000000001137","DOIUrl":"https://doi.org/10.1097/MOG.0000000000001137","url":null,"abstract":"Purpose of review: Chronic constipation remains challenging to manage, particularly when lifestyle measures prove insufficient. With an expanding range of pharmacologic options available, clinicians face the task of choosing the right agent for the right patient. This review explores recent developments in prescription laxatives and their evolving role in practice.Recent findings: Randomized controlled trials have confirmed the safety and efficacy of newer prescription laxative agents including secretagogues (linaclotide, lubiprostone, plecanatide), sodium/hydrogen exchanger isoform 3 (NHE3) inhibitors (tenapanor), serotonin 5-hydroxytryptamine receptor agonists (prucalopride), and bile acid reabsorption inhibitors (elobixibat). Each drug offers its own unique advantages, with new evidence suggesting these therapies may provide symptom relief beyond managing stool consistency alone.Summary: Patients with constipation now have access to a wide range of medications, from over-the-counter osmotic and stimulant agents to prescription laxative combination strategies. This breadth allows clinicians to tailor therapy to diverse pathophysiology and symptom profiles. Yet despite this choice, real-world adherence remains poor and many patients are dissatisfied, reflecting the complexity of treating constipation and frequent mismatches between therapy and patients' most bothersome symptoms. Management should emphasize careful symptom assessment, shared decision-making, and clear expectation setting, while leveraging the available armamentarium.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0